Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Latest Information Update: 24 Nov 2023
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Yttrium-90
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Acronyms IMMUWHY
Most Recent Events
- 31 Mar 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 31 Mar 2022 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 27 Jan 2020 New trial record